Compounds > 9-anilinoacridine
Page last updated: 2024-12-06

9-anilinoacridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID18757
CHEMBL ID49436
SCHEMBL ID902770
MeSH IDM0077955

Synonyms (15)

Synonym
brn 0210868
9-anilinoacridine
9-acridinamine, n-phenyl-
acridine, 9-anilino-
n-phenyl-9-acridinamine
9-(phenylamino)acridine
AKOS002710482
3340-22-5
CHEMBL49436
n-phenylacridin-9-amine
SCHEMBL902770
LNVQBBHYPGFSMX-UHFFFAOYSA-N
acridin-9-yl-phenyl-amine
n-(9-acridinyl)-n-phenylamine #
DTXSID20187044
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID24208Association constant for binding to poly [d(A-T)]1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID1148474Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID24209Association constant for binding to poly [d(G-C)]1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID100307Dose of the drug (mol /kg) providing a 50% life extension in L1210 assays when given at qd 1-5 schedule; No data1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Redox chemistry of the 9-anilinoacridine class of antitumor agents.
AID1148475Toxicity in ip dosed BDF1 mouse allografted with mouse P388 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID116416Maximum percent increase in life span of mice1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID46149Inhibitory concentration against ethidium binding to DNA1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID1148476Toxicity in ip dosed BDF1 mouse allografted with mouse L1210 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1148471Displacement of ethidium bromide from calf thymus DNA by spectrofluorometric analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID18955Lipophilicity index (substitution method)1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID1150556Antitumor activity against mouse L1210 cells allografted in ip dosed C3H/DBA2 F1 mouse assessed as optimum dose required to increase in maximum life span administered as qd for 5 days1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.
AID100911Concentration required to reduce incorporation of [3H]TdR in drug-treated cultures of intracellular Leishmania major to 50% of controls1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID98819Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID210614Compound concentration in mole/kg/day lethal to 10% of mice1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID95456Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID98491Inhibitory concentration to reduce the growth of L1210 cells by 50% after 70 h; No data1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Redox chemistry of the 9-anilinoacridine class of antitumor agents.
AID210610In vitro therapeutic index calculated as the IC50 ratio of Jurkat cells to that of Leishmania major.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID97604Tumor cell selectivity determined as maximal percent increase in life span (ILSmax) at LD10 dosage level in L1210 cells1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Structure-antitumor activity relationships of 9-anilinoacridines using pattern recognition.
AID1148477Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase chromatographic analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1148473Antitumor activity against mouse P388 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID26375Ionisation constant (pKa)1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID116709Drug dose that is lethal to 10% of animals was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (29.55)18.7374
1990's11 (25.00)18.2507
2000's12 (27.27)29.6817
2010's5 (11.36)24.3611
2020's3 (6.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.69 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		7.0410isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
mercaptoethanol
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.		1.9810alkanethiol;
primary alcohol		geroprotector
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		3.1410monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
ethacridine
Ethacridine: A topically applied anti-infective agent.		2.2110acridines
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		6.67420acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		7.420aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
aniline
[no description available]		2.0510anilines;
primary arylamine
proflavine
Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.		1.9810aminoacridinesantibacterial agent;
antiseptic drug;
carcinogenic agent;
chromophore;
intercalator
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		3.1410hexosamine;
secondary amino compound
chelidamic acid
[no description available]		1.9910
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		4.4870acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		2.2110isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
aniline mustard
Aniline Mustard: Alkylating anti-neoplastic agent.		2.0410
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0210taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
4-(9-acridinylamino)aniline
4-(9-acridinylamino)aniline: RN given refers to parent cpd		3.2160
9-(4-methylanilino)-acridine
9-(4-methylanilino)-acridine: RN given refers to parent cpd; structure in first source		2.8840
meglumine antimoniate
Meglumine Antimoniate: ANTIMONY salt of meglumine that is used in the treatment of LEISHMANIASIS.		3.1410
4'-(9-acridinylamino)methanesulfonanilide
4'-(9-acridinylamino)methanesulfonanilide: structure		3.0550
4'-(9-acridinylamino)methanesulfon-o-anisidide
4'-(9-acridinylamino)methanesulfon-o-anisidide: 30-90 times less potent in killing L1210 cells & 200 times less potent in producing single-strand breaks in DNA than m-AMSA; RN given refers to parent cpd; structure in first source		1.9610
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
[no description available]		1.9810
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine
[no description available]		1.9610
jp-1302
[no description available]		1.9610
tamoxifen
[no description available]		2.2110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		7.4110chalcogen;
nonmetal atom		macronutrient
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		03.4680
Experimental Leukemia
[description not available]		01.9510
Breast Cancer
[description not available]		02.9940
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9940
Experimental Neoplasms
[description not available]		02.2110
Acute Lymphoid Leukemia
[description not available]		02.0510
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.0510
Benign Neoplasms
[description not available]		03.3420
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3420
Extravascular Hemolysis
[description not available]		02.0110
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0110
Leishmania Infection
[description not available]		02.9610
Leishmaniasis
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).		02.9610
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3720
Leukemia, Lymphocytic, T Cell
[description not available]		01.9810
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		01.9810
Leishmaniasis, American
[description not available]		01.9810
Leishmaniasis, Cutaneous
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.		01.9810